New Two-Pronged attack on advanced stomach cancer enters testing
NCT ID NCT07400315
Summary
This study is testing a new combination treatment for people with advanced stomach or gastroesophageal junction (GEJ) cancer that is HER2-negative. It combines an immunotherapy drug (QL1706) with a modified chemotherapy regimen (TFOX) as the first treatment for the cancer. The main goal is to see how long patients live without their cancer getting worse and to measure the treatment's safety and effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.